Kalaris Therapeutics, Inc. (KLRS) › Shareholders' EquityKalaris Therapeutics, Inc. (KLRS) — Shareholders' EquityAnnual figures by period end, from SEC filings.2018-12-31: -$30.62M2019-12-31: -$51.50M2020-12-31: $353.06M2021-12-31: $225.27M2022-12-31: $224.52M2023-12-31: -$45.02M2024-12-31: -$96.62M2025-12-31: $78.81M$78.81M2018-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31$78.81M—2026-03-17Balance as of period end2024-12-31-$96.62M—2026-03-17Balance as of period end2023-12-31-$45.02M-120.1%2026-03-17Balance as of period end2022-12-31$224.52M-0.3%2025-03-07Balance as of period end2021-12-31$225.27M-36.2%2024-03-15Balance as of period end2020-12-31$353.06M—2023-02-15Balance as of period end2019-12-31-$51.50M—2022-02-10Balance as of period end2018-12-31-$30.62M—2021-02-12Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)